JBR10

一行要約

完全切除 stage IB-II NSCLC における術後 Vinorelbine/Cisplatin vs 観察の phase III。OS HR 0.69 (94 vs 73 mo) で有意に OS を延長し、術後補助化学療法の有効性を単独 RCT として最も明確に示した trial。LACE meta-analysis の主要 contributor であり、Vinorelbine/Cisplatin が adjuvant standard regimen として確立される根拠。

試験デザイン

• 対象: 完全切除 stage IB (T2N0) or stage II (T1-2N1 or T3N0) NSCLC、ECOG PS 0-1、術後 6 週以内に登録、N=482 (1:1)
• 介入群 (n=242) : Vinorelbine 25 mg/m2 weekly × 16 doses + Cisplatin 50 mg/m2 day 1, 8 Q4W × 4 cycles
• 対照群 (n=240) : 観察のみ
• 層別化: Stage (IB vs II)、N status (N0 vs N1)
• 主要評価項目: OS
• 術後放射線: 許容 (ただし N2 は除外されており大部分は RT なし)

主要結果

• OS (primary) : HR 0.69 (95% CI 0.52–0.91, p=0.04)、median 94 vs 73 mo、5-year OS 69% vs 54%
• RFS: HR 0.60 (95% CI 0.45–0.79, p<0.001)
• Stage 別: Stage II で OS HR 0.59 (benefit 明確)、Stage IB で OS HR 0.79 (有意差なし)
• Chemotherapy compliance: 45% が 4 cycles 完遂。用量強度 median 約60%。好中球減少による dose delay / reduction が主因
• Grade ≥3 AE: 好中球減少 73% (febrile neutropenia 7%)。治療関連死 2 例 (0.8%)
• 9.3-year update (JCO 2010, Butts et al. JClinOncol 2010) : OS benefit が持続 (HR 0.78)。Stage IB は長期で benefit 消失 (HR 1.03)

臨床的意義

• Adjuvant chemo の definitive evidence: Arriagada et al. NEnglJMed 2004 が initial evidence を提供し、JBR10 が最も clear な OS benefit を示した。Absolute 5-year OS gain 15% (69% vs 54%) は NSCLC adjuvant 試験中最大
• Vinorelbine/Cisplatin の標準確立: ANITA と合わせ、vinorelbine/cisplatin が preferred adjuvant regimen として確立。LACE meta-analysis でも vinorelbine doublet の優位性が確認
• Stage IB の controversy: 長期 follow-up で Stage IB の benefit が消失。現在のガイドラインで Stage IB (high-risk features のみ考慮) の推奨が Stage II と異なる根拠
• Compliance の課題: 45% しか計画 4 cycles を完遂できなかった。術後化学療法の忍容性は高齢者・合併症例で特に課題であり、経口 TKI (ADAURA) の adjuvant 使用への動機付け

Open Questions

• Stage IB の adjuvant 適応: 腫瘍径 ≥4 cm / VPI / high-grade 等の high-risk features に基づく選択 — ctDNA MRD との組み合わせ検証
• Adjuvant chemo + TKI / IO sequential: LACE → ADAURA 時代における chemo + Osimertinib sequential の OS benefit
• 高齢者 adjuvant の feasibility: JBR10 の compliance 問題を踏まえた dose-modified regimen / carboplatin substitution の evidence

重要論文 Top 10

1. Winton et al. NEnglJMed 2005 — Primary publication — OS HR 0.69、adjuvant standard
2. Butts et al. JClinOncol 2010 (9.3-year update) — 長期 follow-up — Stage IB benefit 消失
3. ★★★★★ Pignon et al. JClinOncol 2008 (LACE) — Meta-analysis — JBR10 を含む definitive evidence
4. Douillard et al. LancetOncol 2006 (ANITA) — Vinorelbine/Cisplatin adjuvant — companion evidence
5. Wu et al. (ADAURA) — Adjuvant Osimertinib — chemo を超える新時代

関連エンティティ・概念

• 薬剤: Vinorelbine / Cisplatin
• 関連試験: LACE (meta-analysis) / ADAURA (adjuvant Osimertinib) / KEYNOTE-671 (perioperative IO) / CheckMate-816 (neoadjuvant IO)
• ドメイン: lung-cancer-treatment

関連論文

Clinical-Epidemiology

• Asmis et al. JClinOncol 2008 — Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer a review of
• Cuffe et al. JClinOncol 2012 — Adjuvant chemotherapy for non-small-cell lung cancer in the elderly a population-based study in ontario, canada
• Goldstraw et al. Lancet 2011 — Non-small-cell lung cancer

Clinical-NSCLC-Driver negative

• Eberhardt et al. AnnOncol 2015 — 2nd ESMO consensus conference in lung cancer locally advanced stage III non-small-cell lung cancer
• Malhotra et al. AnnOncol 2015 — Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer 4 cm in size an SEER-medicare
• Berry et al. AnnSurgOncol 2015 — Benefit of adjuvant chemotherapy after resection of stage II (T1-2n1m0) non-small cell lung cancer in elderly patients
• NSCLCMetaAnalyses et al. BMJ 1995 — Chemotherapy in non-small cell lung cancer-a meta-analysis using updated data on individual patients
• Wisnivesky et al. BMJ 2011 — Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages
• Gregory et al. BrJCancer 2000 — Vinorelbine-a clinical review
• Wada et al. EurJCardiothoracSurg 1999 — Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegaful) in
• Pathak et al. JAMAOncol 2020 — Association of survival with adjuvant chemotherapy among patients with early-stage non-small cell lung cancer with vs
• Wada et al. JClinOncol 1996 — Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. west japan study group for lung cancer
• Hamada et al. JClinOncol 2005 — Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer
• Gridelli et al. JClinOncol 2007 — Lung cancer in the elderly
• Pepe et al. JClinOncol 2007 — Adjuvant vinorelbine and cisplatin in elderly patients national cancer institute of canada and intergroup study JBR.10
• Pignon et al. JClinOncol 2008 — Lung adjuvant cisplatin evaluation a pooled analysis by the LACE collaborative group
• Strauss et al. JClinOncol 2008 — Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer CALGB 9633 with
• Arriagada et al. JClinOncol 2010 — Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in
• Butts et al. JClinOncol 2010 — Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and
• Felip et al. JClinOncol 2010 — Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage
• Tsao et al. JClinOncol 2015 — Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing
• Douillard et al. JThoracOncol 2010 — Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer subgroup analysis of the lung
• Leighl et al. JThoracOncol 2010 — Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small
• Watanabe et al. JpnJClinOncol 2017 — Neoadjuvant and adjuvant therapy for stage III non-small cell lung cancer
• Douillard et al. LancetOncol 2006 — Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA
• Alam et al. LungCancer 2005 — Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. an analysis of national cancer
• Bennouna et al. LungCancer 2011 — Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy subgroup
• Arriagada et al. NEnglJMed 2004 — Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
• Winton et al. NEnglJMed 2005 — Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

Clinical-Supportive care

• Park et al. AnnOncol 2013 — Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung